BioLargo Files 8-K on Shareholder Vote & Financials

Ticker: BLGO · Form: 8-K · Filed: Jun 25, 2025 · CIK: 880242

Sentiment: neutral

Topics: corporate-governance, financial-reporting

TL;DR

BioLargo filed an 8-K for shareholder votes and financials.

AI Summary

On June 19, 2025, BioLargo, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The company, formerly known as Nuway Medical Inc. and Nuway Energy Inc., is incorporated in Delaware and headquartered in Westminster, California.

Why It Matters

This filing indicates important corporate actions are being taken, including matters requiring shareholder approval and the submission of financial information, which are crucial for investors to understand the company's governance and financial health.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information suggesting immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for BioLargo, Inc.?

The primary purpose is to report on the submission of matters to a vote of security holders and to file financial statements and exhibits.

On what date was the earliest event reported in this filing?

The earliest event reported was on June 19, 2025.

What are some of BioLargo, Inc.'s former company names mentioned in the filing?

BioLargo, Inc. was formerly known as NUWAY MEDICAL INC and NUWAY ENERGY INC.

Where are BioLargo, Inc.'s principal executive offices located?

BioLargo, Inc.'s principal executive offices are located at 14921 Chestnut St., Westminster, California.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding BIOLARGO, INC. (BLGO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing